Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04837222 | A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma | completed | — | 1,000 | TakedaINDUSTRY | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05634785 | CD30 CAR for CD30+ NSGCT | completed | Phase 2 | 2 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05751486 |
| A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma |
| completed |
| Phase 1 |
| 64 |
| Shanghai Junshi Bioscience Co., Ltd.OTHER |
| 1 |
| Jul 7, 2026 |
| clinicaltrials |
| NCT06038526 | Evaluation of Canakinumab in High-Risk Former-Smokers | completed | Phase 2 | 41 | Peter ShieldsOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06153238 | A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma | completed | Phase 1 | 322 | SandozINDUSTRY | 18 | Jul 7, 2026 | clinicaltrials |
| NCT06161922 | Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy | completed | — | 600 | Fudan UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06182163 | Reduce Sedentary Time in Acute Lymphoblastic Leukemia(ReSeT in ALL) | completed | N/A | 20 | Children's Hospital Los AngelesOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06403436 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors(TT-CSP-001) | completed | Phase 1 | 45 | TOLREMO therapeutics AGINDUSTRY | 3 | Jul 7, 2026 | clinicaltrials |
| NCT07687758 | Non-Invasive Risk Stratification for Hepatocellular Carcinoma in HCV-Related Compensated Advanced Chronic Liver Disease Following Sustained Virological Response: Validation of the aMAP Score(HCV-aMAP) | completed | — | 571 | Siriraj HospitalOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07689006 | Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens | completed | — | 341 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 7, 2026 | clinicaltrials |
| NCT00113360 | RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma | completed | Phase 2 | 67 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT00449748 | Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis | completed | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT01916785 | OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)(OPTIM-DASA) | completed | Phase 2 | 289 | Versailles HospitalOTHER | 2 | Jul 6, 2026 | clinicaltrials |
| NCT02843568 | Improving Pulmonary Function Following Radiation Therapy | completed | N/A | 122 | University of Wisconsin, MadisonOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT02888964 | Pioglityazone and Imatinib for CML Patients(ACTIM) | completed | Phase 2 | 27 | Versailles HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT02896842 | A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML(OPTIMIMATINIB) | completed | Phase 2 | 139 | Versailles HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04106856 | Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer(SHAPER) | completed | Phase 1 | 22 | University of UtahOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04609566 | Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors | completed | Phase 2 | 161 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04718584 | the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors | completed | Phase 2 | 27 | Dragonboat Biopharmaceutical Company LimitedINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05139225 | A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma | completed | Phase 1 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06472778 | A Real-world Study in Participants With Smoldering Multiple Myeloma | completed | — | 408 | Janssen-Cilag Ltd.INDUSTRY | 5 | Jul 6, 2026 | clinicaltrials |
| NCT06745804 | Study of 68Ga-R10602 | completed | Phase 1 | 27 | Radionetics OncologyINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT01813136 | Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma | completed | Phase 2 | 168 | Centre Leon BerardOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT02088775 | PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer | completed | N/A | 44 | Fox Chase Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT02344680 | Liver Fibrosis in Zambian HIV-HBV Co-infected Patients | completed | — | 349 | University of Alabama at BirminghamOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT02346253 | High-Dose Brachytherapy in Treating Patients With Prostate Cancer | completed | N/A | 146 | Stanford UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT03603002 | Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer | completed | N/A | 6 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04000880 | Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health(AMPLIFY) | completed | N/A | 603 | University of Alabama at BirminghamOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04401995 | Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab | completed | Phase 2 | 9 | Diwakar DavarOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05230004 | Innovative Prosthetic Systems for Pediatric Limb Loss to Accommodate Growth | completed | N/A | 35 | University of PennsylvaniaOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05256472 | A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma | completed | Phase 2 | 28 | AkesoINDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05375994 | Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients(RAMP204) | completed | Phase 1 / Phase 2 | 12 | Verastem, Inc.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05824585 | DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | completed | Phase 1 | 17 | Dizal PharmaceuticalsINDUSTRY | 2 | Jul 2, 2026 | clinicaltrials |
| NCT07682012 | LungVision AI-Augmented Fluoroscopic Navigation for Intraoperative Pulmonary Nodule Localization | completed | N/A | 14 | Tri-Service General Hospital (TSGH)OTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07682285 | Taiwanese Green Propolis for Lipid Profiles, Fatigue, and Quality of Life in Oral Cavity Cancer Survivors(TGP-OCS) | completed | N/A | 25 | Taipei Medical UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT00183820 | Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma | completed | Phase 2 | 30 | University of Southern CaliforniaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT01772706 | Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer(LaserMucite) | completed | N/A | 97 | Institut Cancerologie de l'OuestOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT01862315 | Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC) | completed | Phase 2 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT02911259 | Suction on Post-Operative Chest Tubes(SPOCT) | completed | N/A | 230 | Rigshospitalet, DenmarkOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03179904 | TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer | completed | Phase 2 | 17 | Mayo ClinicOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04116970 | Endobronchial Ultrasound-Guided Transbronchial Needle-Aspiration With Suction in Obtaining Samples From Patients With Suspected Nodal Metastatic Lung Cancer(EBUS-Suction) | completed | N/A | 50 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05397132 | Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies | completed | — | 88 | Duke UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05698199 | Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM) | completed | Phase 1 | 10 | Immunomic Therapeutics, Inc.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06179511 | Study of AZD9829 in CD123+ Hematological Malignancies | completed | Phase 1 / Phase 2 | 56 | AstraZenecaINDUSTRY | 10 | Jul 1, 2026 | clinicaltrials |
| NCT06203912 | Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 3 | Elvira UmyarovaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07678099 | Screening Colonoscopy in Breast Cancer Patients | completed | N/A | 216 | Haydarpasa Numune Training and Research HospitalOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03801304 | Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer(VinMetAtezo) | completed | Phase 2 | 80 | University Hospital, BrestOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT04294498 | Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection | completed | Phase 2 | 30 | National Taiwan University HospitalOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT04740307 | Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004) | completed | Phase 2 | 116 | Merck Sharp & Dohme LLCINDUSTRY | 9 | Jun 30, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 7, 2026source: clinicaltrials